SG11202101524RA - T cell receptor constructs and uses thereof - Google Patents

T cell receptor constructs and uses thereof

Info

Publication number
SG11202101524RA
SG11202101524RA SG11202101524RA SG11202101524RA SG11202101524RA SG 11202101524R A SG11202101524R A SG 11202101524RA SG 11202101524R A SG11202101524R A SG 11202101524RA SG 11202101524R A SG11202101524R A SG 11202101524RA SG 11202101524R A SG11202101524R A SG 11202101524RA
Authority
SG
Singapore
Prior art keywords
cell receptor
receptor constructs
constructs
cell
receptor
Prior art date
Application number
SG11202101524RA
Inventor
Vikram Juneja
Jaewon Choi
Original Assignee
Biontech Us Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biontech Us Inc filed Critical Biontech Us Inc
Publication of SG11202101524RA publication Critical patent/SG11202101524RA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/50—Colon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464401—Neoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG11202101524RA 2018-08-16 2019-08-16 T cell receptor constructs and uses thereof SG11202101524RA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862764817P 2018-08-16 2018-08-16
US201962810112P 2019-02-25 2019-02-25
PCT/US2019/046876 WO2020037239A1 (en) 2018-08-16 2019-08-16 T cell receptor constructs and uses thereof

Publications (1)

Publication Number Publication Date
SG11202101524RA true SG11202101524RA (en) 2021-03-30

Family

ID=69525945

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202101524RA SG11202101524RA (en) 2018-08-16 2019-08-16 T cell receptor constructs and uses thereof

Country Status (14)

Country Link
US (1) US20210340215A1 (en)
EP (1) EP3837279A4 (en)
JP (2) JP2021533777A (en)
KR (1) KR20210074277A (en)
CN (1) CN112888707A (en)
AU (1) AU2019321608B2 (en)
BR (1) BR112021002826A2 (en)
CA (1) CA3109232A1 (en)
IL (1) IL280718A (en)
MX (1) MX2021001837A (en)
PH (1) PH12021550307A1 (en)
SG (1) SG11202101524RA (en)
TW (1) TW202021982A (en)
WO (1) WO2020037239A1 (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012104843A1 (en) 2011-02-06 2012-08-09 Yeda Research And Development Co.Ltd. At The Weizmann Institute Of Science Affinity maturated t cell receptors and use thereof
EP3810180A4 (en) * 2018-06-19 2022-03-30 BioNTech US Inc. Neoantigens and uses thereof
CN113631172A (en) * 2019-01-25 2021-11-09 宾夕法尼亚大学理事会 Compositions and methods for targeting mutant RAS
CA3130618A1 (en) 2019-02-20 2020-08-27 Fred Hutchinson Cancer Research Center Binding proteins specific for ras neoantigens and uses thereof
EP4168028A4 (en) * 2020-06-17 2024-10-23 Tscan Therapeutics Inc Sars-cov-2 immunodominant peptides and uses thereof
IL276599A (en) * 2020-08-09 2022-03-01 Yeda Res & Dev Mage-a1 specific t cell receptor and uses thereof
WO2022036103A1 (en) * 2020-08-13 2022-02-17 Rootpath Genomics, Inc. Compositions and methods for antigen identification
US11421015B2 (en) 2020-12-07 2022-08-23 Think Therapeutics, Inc. Method of compact peptide vaccines using residue optimization
CN117529492A (en) * 2021-01-21 2024-02-06 鹿特丹伊拉斯谟大学医疗中心 T cells for therapy
EP4320144A1 (en) * 2021-04-05 2024-02-14 Janssen Biotech, Inc. Calr and jak2 t-cell receptors
EP4323379A2 (en) * 2021-04-14 2024-02-21 Tscan Therapeutics, Inc. Magec2 immunogenic peptides, binding proteins recognizing magec2 immunogenic peptides, and uses thereof
EP4326751A1 (en) * 2021-04-21 2024-02-28 The United States of America, as represented by the Secretary, Department of Health and Human Services Hla class i-restricted t cell receptors against ras with q61k mutation
US11464842B1 (en) 2021-04-28 2022-10-11 Think Therapeutics, Inc. Compositions and method for optimized peptide vaccines using residue optimization
JP2024518403A (en) * 2021-05-03 2024-05-01 ユニバーシティ オブ ピッツバーグ －オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション T cell receptor (TCR) that targets the minor histocompatibility antigen HA-1
WO2023077100A1 (en) * 2021-10-29 2023-05-04 Yafei Hou T cell receptor recognizing r175h mutation in p53 and its application
WO2023220718A1 (en) * 2022-05-13 2023-11-16 Fred Hutchinson Cancer Center Binding proteins specific for ras neoantigens and uses thereof
WO2023230014A1 (en) * 2022-05-23 2023-11-30 Affini-T Therapeutics, Inc. Binding proteins and engineered cells specific for neoantigens and uses thereof
CN117264043B (en) * 2022-06-14 2024-05-10 上海镔铁生物科技有限责任公司 T cell receptor targeting KRAS G12V mutant polypeptide and application thereof
WO2024039576A2 (en) * 2022-08-19 2024-02-22 Memorial Sloan-Kettering Cancer Center T cell receptors targeting ras mutations and uses thereof
WO2024148181A2 (en) * 2023-01-04 2024-07-11 Board Of Regents, The University Of Texas System T cell receptors targeting the highly prevalent kras g12c mutation on hla-a*11:01 in lung cancer
WO2024148183A2 (en) * 2023-01-04 2024-07-11 Board Of Regents, The University Of Texas System T cell receptors targeting the highly prevalent kras g12v mutation on hla-a*03:01 in lung cancer
WO2024148185A2 (en) * 2023-01-04 2024-07-11 Board Of Regents, The University Of Texas System T cell receptors targeting the highly prevalent kras g12v mutation on hla-a*11:01 in lung cancer
WO2024148178A2 (en) * 2023-01-04 2024-07-11 Board Of Regents, The University Of Texas System T cell receptors targeting the highly prevalent kras g12c mutation on hla-a*03:01 in lung cancer
WO2024149347A1 (en) * 2023-01-13 2024-07-18 北京可瑞生物科技有限公司 Antigen binding protein and use thereof
WO2024163935A2 (en) * 2023-02-03 2024-08-08 Affini-T Therapeutics, Inc. Host cells bearing kras binding protein and knockout of endogenous tcr and methods of use thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150104441A1 (en) * 2013-10-11 2015-04-16 Oslo Universitetssykehus Hf Identification of disease-driving antigens
WO2016085904A1 (en) * 2014-11-26 2016-06-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-mutated kras t cell receptors
CA2980292A1 (en) * 2015-03-23 2016-09-29 The Johns Hopkins University Hla-restricted epitopes encoded by somatically mutated genes
EP3347374A1 (en) * 2015-09-09 2018-07-18 Immune Design Corp. Ny-eso-1 specific tcrs and methods of use thereof
SG10201913868XA (en) * 2015-09-15 2020-03-30 The United States Of America As Represented By The Secretary T cell receptors recognizing hla-cw8 restricted mutated kras
CR20180519A (en) * 2016-03-31 2019-03-05 Neon Therapeutics Inc NEOANT US AND METHODS OF USE
CN108395479B (en) * 2017-02-06 2021-07-16 高军 T cell receptor related to KRAS gene mutation

Also Published As

Publication number Publication date
CN112888707A (en) 2021-06-01
TW202021982A (en) 2020-06-16
MX2021001837A (en) 2021-07-16
JP2024060024A (en) 2024-05-01
CA3109232A1 (en) 2020-02-20
EP3837279A1 (en) 2021-06-23
BR112021002826A2 (en) 2021-05-04
KR20210074277A (en) 2021-06-21
PH12021550307A1 (en) 2021-10-25
JP2021533777A (en) 2021-12-09
IL280718A (en) 2021-03-25
AU2019321608B2 (en) 2024-07-25
US20210340215A1 (en) 2021-11-04
EP3837279A4 (en) 2022-05-11
AU2019321608A1 (en) 2021-03-18
WO2020037239A1 (en) 2020-02-20

Similar Documents

Publication Publication Date Title
IL280718A (en) T cell receptor constructs and uses thereof
IL274921A (en) Bcma-targeting chimeric antigen receptor, and uses thereof
IL271435A (en) T cell receptors
EP3630980A4 (en) Chimeric antigen receptor cell preparation and uses thereof
HK1258274A1 (en) Antibody/t-cell receptor chimeric constructs and uses thereof
SG10201913579WA (en) Chimeric antibody/t-cell receptor constructs and uses thereof
EP3472208C0 (en) T cell receptors and uses thereof
EP3567049A4 (en) Chimeric antigen receptor and natural killer cells expressing same
EP3733839A4 (en) Antibody-modified chimeric antigen receptor modified t cell and uses thereof
EP3573660A4 (en) Improved antibody-coupled t cell receptor constructs and therapeutic uses thereof
IL257295B (en) Chimeric antigen receptors, and t cells in which chimeric antigen receptor is expressed
SG11201909751TA (en) Human alpha fetoprotein-specific t cell receptors and uses thereof
IL276746A (en) Kir3dl3 as an hhla2 receptor, anti-hhla2 antibodies, and uses thereof
IL276556A (en) Cyclin a1 specific t cell receptors and uses thereof
IL273247A (en) Novel cell line and uses thereof
SG11202001011XA (en) Chimeric antigen receptor and car-t cells that bind cxcr5
EP3765491C0 (en) Inducible t cell receptors and uses thereof
GB2585607B (en) Chimeric antigen receptor and application thereof
GB201721831D0 (en) T cell antigen receptor chimera